Melanoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older
• People whose general health and activity level meets a specific performance standard (rated 0 or 1 on a scale used by doctors to measure how much a condition affects daily activities — confirm with trial site)
• People who have signed and dated a consent form before any study procedures begin
• People who have been receiving a PD-1 inhibitor treatment (either alone or combined with a CTLA-4 inhibitor) as their first treatment for advanced skin melanoma that cannot be surgically removed, have been on it for at least 3 months, and whose cancer has since grown or spread (meaning at least one tumour has enlarged by 30% or more, or new tumours have appeared)
• People who were receiving PD-1 inhibitor treatment after surgery (as a preventive measure) and whose cancer has since returned and spread in a way that cannot be surgically removed, confirmed by biopsy
• People who have at least one growing or new tumour that a specialist determines can safely receive targeted radiation treatment, AND at least one other growing or new tumour (that will not be irradiated) that can be measured by CT or MRI scan — with up to four areas allowed for radiation targeting
• People for whom there is no medical reason preventing them from continuing immunotherapy after the radiation treatment

Who may not be able to join:

• People who are unable to understand the study information or take part in the required procedures
• People who are pregnant or breastfeeding — participants must agree to use reliable contraception during treatment and for 3 months after
• People who have needed regular doses of corticosteroids (more than 10 mg of prednisone per day, or equivalent) or other immune-suppressing medications within the 30 days before starting the study (inhaled or topical steroids and certain replacement doses are exceptions — confirm with trial site)
• People who currently have an active infection that requires treatment with systemic (whole-body) medicines
• People who are receiving or have received other anti-cancer treatments within 30 days before or after this trial's treatment, apart from PD-1 or CTLA-4 inhibitor therapies
• People who have previously had radiation treatment in a way that would prevent the type of precision radiation used in this trial
• People whose tumours are in a location, or are too large or too numerous, for precision radiation treatment to be appropriate
• People who currently have cancer that has spread to the brain or central nervous system — unless those brain/central nervous system tumours were previously treated (by surgery, radiation, or similar), the person has no symptoms from them, and no steroids or anti-seizure medications are currently required
• People who have had another type of cancer in the past, unless they have been free of that cancer for at least 5 years — exceptions may include certain completely removed skin cancers (non-melanoma) or successfully treated early-stage cancers confined to one area (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.